Anticancer Pharmaceutical Laboratory Services (PBMpharma™)

• The goal of anticancer drug discovery and development programs is to design selective ligands that act on single targets of diseases to obtain effective and safe drugs with low side effects. However, there is a decline in the number of drugs introduced into clinical practice over the past decades. One reason may be because pathogenesis of most diseases is rather multifactorial in nature, and not due to a single causing agent. Another reason is that most diseases diversify their pathogenic mechanisms rendering target-oriented therapeutic effects incomplete.
• Although the pathophysiology of the metastasis disease is not fully understood in cancer patients, the knowledge that its pathogenesis involves multiple factors obliges effective therapeutic approaches to shift from a conventional “one target, one drug” to a “multi-target” model.
• Persona Biomed’s scientists have identified molecules and genes associated to pathogenic pathways of metastatic cancers, whose combined expression pattern in tumor biopsies has been correlated with major pathophysiological and evolutionary features of cancer patients and even with their treatment response.
• Next, carcinogenic factors with the ability to induce such metastasis-associated biomarker genes and molecules in cultured cancer and cancer microenvironmental cells have also been identified.
• On this basis, Persona Biomed’s scientists have now developed unique “multitarget” drug screening bioassays enabling the accurate detection of chemical compounds and biologics interfering with the whole expression of metastasis biomarkers by cancer cells and cancer microenvironment-associated cells.
• Persona Biomed is now commercializing under the trademark of PBMphama™ a growing list of clinically-relevant and unique in vitro and in vivo drug screening bioassays. The main purpose is contributing to muti-target anti-carcinogenic and anti-metastatic therapy through the discovery of drugs with inhibitory effects on the whole family of molecules and genes associated to the pathogenic mechanism of most prevalent cancers and their concomitant immune-inflammatory impairment.
• All the bioassays are conducted in accordance with worldwide regulatory requirements, and in compliance with good laboratory practice (GLP) regulations, audited by an external Quality Assurance Unit.

Service Catalog

Drug Screening Services